AI TRENDS | Novo Nordisk China Says Semaglutide Injection Wins NMPA Approval for MASH Indication

According to Wallstreetcn, Novo Nordisk China said semaglutide injection, sold under the brand name Wegovy, won approval from China's National Medical Products Administration for its MASH indication, making it the first and only GLP-1RA approved to treat MASH in non-cirrhotic adults with moderate to severe liver fibrosis (F2-F3).